ArticleThe British and Irish orthoptic journal2022
Clinical Utility of 'Peekaboo Vision' Application for Measuring Grating Acuity in Children with Down Syndrome.
Article in The British and Irish orthoptic journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
- Children's visual acuity tests without professional supervision: a prospective repeated measures study.Eye (London, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peekaboo Vision is an iPad grating acuity app built with typically developing children in mind. Given the ease of using this app in the pediatric age group, this study determined its clinical utility in children with Down syndrome. Two groups of participants (children with Down syndrome and age-matched controls) were included. Presenting binocular grating acuity was measured using Peekaboo Vision and Teller acuity cards II in random order. Parents' feedback about their child's engagement and time taken to complete each test was documented. Thirty-seven children with Down syndrome (males = 23; mean age = 8.1 ± 4.2 years) and 28 controls (males = 15; mean age = 8.71 ± 3.84 years) participated. Time taken to complete the tests was comparable (p = 0.83) in children with Down syndrome. Controls were significantly faster with Peekaboo Vision (p = 0.01). Mean logMAR acuities obtained with Peekaboo Vision (0.16 ± 0.34) and Teller acuity cards II (0.63 ± 0.34) were significantly different (p < 0.001) in children with Down syndrome (mean difference in acuities: -0.44 ± 0.38 logMAR (95% LoA: -1.18 to 0.3). For controls, the mean logMAR acuity with Peekaboo Vision (-0.13 ± 0.12) and Teller acuity cards II (0.12 ± 0.09) was also found to be significantly different (p < 0.001) (mean difference in acuities: -0.24 ± 0.14 logMAR (95% LoA: -0.51 to 0.03) Peekaboo Vision test can be used on children with Down syndrome. Peekaboo Vision and Teller acuity cards II can be used independently but not interchangeably. The differences in the acuity values between the two tests could be a result of the differences in the thresholding paradigms, different testing mediums and the range of acuities covered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.